These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36627202)

  • 1. High-cost drugs for rare diseases: their expenditure and value based on a regional area-based study.
    Manea S; Visonà Dalla Pozza L; Minichiello C; Altieri L; Mazzucato M; Bonin M; De Ambrosis P; Borgonovi E; Facchin P
    Health Serv Manage Res; 2024 Feb; 37(1):52-60. PubMed ID: 36627202
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of orphan drugs on Latvian budget.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).
    Lee SH; Yoo SL; Bang JS; Lee JH
    Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
    Schlander M; Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
    Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R
    Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The impact of the use of treatments not included in the reimbursement classes in the care of rare patients: a real world study.].
    Mazzucato M; Minichiello C; Visonà Dalla Pozza L; Vianello A; Toto E; De Lorenzi M; Scroccaro G; Facchin P
    Recenti Prog Med; 2022; 113(7):440-450. PubMed ID: 35852080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variables affecting pricing of orphan drugs: the Italian case.
    Jommi C; Listorti E; Villa F; Ghislandi S; Genazzani A; Cangini A; Trotta F
    Orphanet J Rare Dis; 2021 Oct; 16(1):439. PubMed ID: 34666819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
    Orofino J; Soto J; Casado MA; Oyagüez I
    Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy.
    Di Brino E; Yan S; Tomic R; Panebianco M; Dlotko E; Stern L; Basile M; Rumi F; Cicchetti A; Marino R
    J Med Econ; 2023; 26(1):554-564. PubMed ID: 37039544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.
    Schlander M; Dintsios CM; Gandjour A
    Value Health; 2018 May; 21(5):525-531. PubMed ID: 29753348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of patient access to orphan drugs in Turkey.
    Koçkaya G; Atalay S; Oğuzhan G; Kurnaz M; Ökçün S; Sar Gedik Ç; Şaylan M; Şencan N
    Orphanet J Rare Dis; 2021 Feb; 16(1):68. PubMed ID: 33549137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China.
    Xin XX; Guan XD; Shi LW
    Orphanet J Rare Dis; 2016 Jun; 11(1):74. PubMed ID: 27266878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.
    Carreras MJ; Tomás-Guillén E; Farriols A; Renedo-Miró B; Valdivia C; Vidal J; Saura C; Carles J; Felip E; Gorgas MQ; Tabernero J; Monterde J
    Curr Oncol; 2023 Aug; 30(9):7984-8004. PubMed ID: 37754495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 19. The Tuscany Regional Network for rare diseases: from European Reference Networks' experience to registry based organisation and management model for rare diseases.
    Pieroni F; Marrucci S; Di Pietro L; Berni C; Scaletti C
    Orphanet J Rare Dis; 2023 Oct; 18(1):324. PubMed ID: 37833795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drugs expenditure in the Netherlands in the period 2006-2012.
    Kanters TA; Steenhoek A; Hakkaart L
    Orphanet J Rare Dis; 2014 Oct; 9():154. PubMed ID: 25304026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.